Athanor Capital’s Five Prime Therapeutics FPRX Stock Holding History
Bought
Maintained
Sold
Athanor Capital's FPRX Position: Q2 2021 in Review
Athanor Capital sold out of Five Prime Therapeutics (FPRX) in Q2 2021, closing a stake of 23,159 shares — an estimated $872K sold.
Athanor Capital first reported a position in FPRX in Q2 2019 and held it in 6 quarters. The position peaked at $1.31M in Q4 2020. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Athanor Capital reported no remaining Five Prime Therapeutics position as of Q2 2021 after selling out during the quarter.
- Athanor Capital sold 23,159 Five Prime Therapeutics shares in Q2 2021, an estimated $872K.
- Athanor Capital first reported a position in Five Prime Therapeutics in Q2 2019 and held it in 6 quarters.
- Athanor Capital's Five Prime Therapeutics position peaked at $1.31M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics as of Q2 2021.
Based on Athanor Capital's 13F filing for Q2 2021, filed 16 Aug 2021.